MYCN and the epigenome

Frontiers in Oncology

Volumn 3 JAN, Issue , 2013, Pages

  He, Stanley ^a   Liu, Zhihui ^a   Oh, Doo Yi ^a   Thiele, Carol J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epigenetics; Ezh2; Hat; Hdac; Mycn; Nucleosome; RNA polymerase II; Transcriptional activation

Indexed keywords

3 DEAZANEPLANOCIN A; ANTINEOPLASTIC AGENT; BMI1 PROTEIN; BRG1 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; HISTONE ACETYLTRANSFERASE GCN5; HISTONE DEACETYLASE; JQ 1; JQ1; ORNITHINE DECARBOXYLASE; RETINOIC ACID; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

APOPTOSIS; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; EPIGENETICS; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; MICROARRAY ANALYSIS; NEUROBLASTOMA; NONHUMAN; ONCOGENE; ONCOGENE MYCN; PROTEIN PROCESSING; REVIEW; RNA TRANSLATION;

EID: 84887823779     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00001     Document Type: Review

References (59)

1. Allard, S., Utley, R. T., Savard, J., Clarke, A., Grant, P., Brandl, C. J., et al. (1999). NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p. EMBO J. 18, 5108-5119.
2. Ayer, D. E. (1999). Histone deacetylases: transcriptional repression with SINers and NuRDs. Trends Cell Biol. 9, 193-198
3. Bernstein, B. E., Meissner, A., and Lander, E. S. (2007). The mammalian epigenome. Cell 128, 669-681.
4. Bintu, L., Ishibashi, T., and Lander, E. S. (2012). Nucleosomal elements that control the topography of the barrier to transcription. Cell 151, 738-749.
5. Bisgrove, D. A., Mahmoudi, T., Henklein, P., and Verdin, E. (2007). Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. U.S.A. 104, 13690-13695.
6. Calao, M., Sekyere, E. O., Cui, H. J., Cheung, B. B., Thomas, W. D., Keating, J., et al. (2012). Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene doi: 10.1038/onc.2012.368 [Epub ahead of print].
7. Cetinkaya, C., Hultquist, A., Su, Y., Wu, S., Bahram, F., Påhlman, S., et al. (2007). Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. Mol. Cancer Ther. 6, 2634-2641.
8. Chan, H. M., and La Thangue, N. B. (2001). p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114(Pt 13), 2363-2373.
9. Cheng, S. W., Davies, K. P., Yung, E., Beltran, R. J., Yu, J., and Kalpana, G. V. (1999). c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat. Genet. 22, 102-105.
10. Cirillo, L. A., Lin, F. R., Cuesta, I., Friedman, D., Jarnik, M., and Zaret, K. S. (2002). Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 9, 279-289.
11. Cole, M. D., and Cowling, V. H. (2008). Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat. Rev. Mol. Cell Biol. 9, 810-815.
12. Cotterman, R., Jin, V. X., Krig, S. R., Lemen, J. M., Wey, A.,and Farnham, P. J., et al. (2008). N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res. 68, 9654-9662.
13. Cowling, V. H., and Cole, M. D. (2010). Myc regulation of mRNA cap methylation. Genes Cancer 1, 576-579.
14. Cui, H., Hu, B., Li, T., Ma, J., Alam, G., Gunning, W. T., et al. (2007). Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am. J. Pathol. 170, 1370-1378.
15. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917.
16. Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., and Ozato, K. (2003). The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U.S.A. 100, 8758-8763.
17. Dhalluin, C., J. Carlson, E., Zeng, L., He, C., Aggarwal, A. K., and Zhou, M. M. (1999). Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496.
18. Filion, G. J., van Bemmel, J. G., Braunschweig, U., Talhout, W., Kind, J., Ward, L. D., et al. (2010). Systematic protein location mapping reveals five principal chromatin types in Drosophila cells. Cell 143, 212-224.
19. Frank, S. R., Parisi, T., Taubert, S., Fernandez, P., Fuchs, M., Chan, H. M., et al. (2003). MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4, 575-580.
20. Goto, S., Umehara, S., Gerbing, R. B., Stram, D. O., Brodeur, G. M., Seeger, R. C., et al. (2001). Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 92, 2699-2708.
21. Guccione, E., Martinato, F., Finocchiaro, G., Luzi, L., Tizzoni, L., Dall' Olio, V., et al. (2006). Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol. 8, 764-770.
22. Iraci, N., Diolaiti, D., Papa, A., Porro, A., Valli, E., Gherardi, S., et al. (2011). A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 71, 404-412.
23. Kim, J., Woo, A. J., Chu, J., Snow, J. W., Fujiwara, Y., Kim, C. G., et al. (2010). A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313-324.
24. Klempnauer, K. H. (1989). Association of v-myc protein with chromatin. Oncogene 4, 115-118.
25. Knoepfler, P. S., and Eisenman, R. N. (1999). Sin meets NuRD and other tails of repression. Cell 99, 447-450.
26. Knoepfler, P. S., Zhang, X. Y., Cheng, P. F., Gafken, P. R., McMahon, S. B., and Eisenman, R. N. (2006). Myc influences global chromatin structure. EMBO J. 25, 2723-2734.
27. Laherty, C. D., Yang, W. M., Sun, J. M., Davie, J. R., Seto, E., and Eisenman, R. N. (1997). Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89, 349-356.
28. Lawlor, E. R., and Thiele, C. J. (2012). Epigenetic changes in pediatric solid tumors: promising new targets. Clin. Cancer Res. 18, 2768-2779.
29. Lehmann, L., Ferrari, R., Vashisht, A. A., Wohlschlegel, J. A., Kurdistani, S. K., and Carey, M. (2012). Polycomb repressive complex 1 (PRC1) disassembles RNA polymerase II preinitiation complexes. J. Biol. Chem. 287, 35784-35794.
30. Lin, C. Y., Loven, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., et al. (2012). Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56-67.
31. Lucarelli, E., Kaplan, D. R., and Thiele, C. J. (1995). Selective regulation of TrkA and TrkB receptors by retinoic acid and interferon-gamma in human neuroblastoma cell lines. J. Biol. Chem. 270, 24725-24731.
32. Malynn, B. A., de Alboran, I. M., O'Hagan, R. C., Bronson, R., Davidson, L., DePinho, R. A., et al. (2000). N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 14, 1390-1399.
33. Martinez-Cerdeno, V., Lemen, J. M., O'Hagan, R. C., Bronson, R., Davidson, L., DePinho, R. A., et al. (2012). N-Myc and GCN5 regulate significantly overlapping transcriptional programs in neural stem cells. PLoS ONE 7:e39456. doi: 10.1371/journal.pone.0039456
34. McEwan, I. J., Dahlman-Wright, K., Ford, J., and Wright, A. P (1996). Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding. Biochemistry 35, 9584-9593.
35. McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D., and Cole, M. D. (1998). The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94, 363-374.
36. McMahon, S. B., Wood, M. A., and Cole, M. D. (2000). The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol. Cell. Biol. 20, 556-562.
37. Neri, F., Zippo, A., Krepelova, A., Cherubini, A., Rocchigiani, M., and Oliviero, S. (2012). Myc regulates the transcription of the PRC2 gene to control the expression of developmental genes in embryonic stem cells. Mol. Cell. Biol. 32, 840-851.
38. Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., et al. (2012). c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151, 68-79.
39. Ochiai, H., Takenobu, H., Nakagawa, A., Yamaguchi, Y., Kimura, M., Ohira, M., et al. (2010). Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Oncogene 29, 2681-2690.
40. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. (1996). The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959.
41. Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., et al. (2012). BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 120, 2843-2852.
42. Park, J. R., Villablanca, J. G., London, W. B., Gerbing, R. B., Haas-Kogan, D., Adkins, E. S., et al. (2009). Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr. Blood Cancer 52, 44-50.
43. Patel, J. H., Du, Y., Ard, P. G., Phillips, C., Carella, B., Chen, C. J., et al. (2004). The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol. Cell. Biol. 24, 10826-10834.
44. Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., et al. (2010). c-Myc regulates transcriptional pause release. Cell 141, 432-445.
45. Romero, O. A., Setien, F., John, S., Gimenez-Xavier, P., Gómez-López, G., Pisano, D., et al. (2012). The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol. Med. 4, 603-616.
46. Schwab, M., Alitalo, K., Klempnauer, K. H., Varmus, H. E., Bishop, J. M., Gilbert, F., et al. (1983). Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305, 245-248.
47. Simon, J. A., and Kingston, R. E. (2009). Mechanisms of polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 10, 697-708.
48. Soufi, A., Donahue, G., and Zaret, K. S. (2012). Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 151, 994-1004.
49. Stone, J., de Lange, T., Ramsay, G., Jakobovits, E., Bishop, J. M., Varmus, H., et al. (1987). Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol. Cell. Biol. 7, 1697-1709.
50. Strahl, B. D., and Allis, C. D. (2000). The language of covalent histone modifications. Nature 403, 41-45.
51. Telford, D. J., and Stewart, B. W. (1990). Structural features of the amplified N-myc oncogene detected by micrococcal nuclease digestion of neuroblastoma cell nuclei. Biochem. Int. 21, 1025-1032.
52. Thiele, C. J., Reynolds, C. P., and Israel, M. A. (1985). Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313, 404-406.
53. Valentijn, L. J., Koster, J., Haneveld, F., Aissa, R. A., van Sluis, P., Broekmans, M. E., et al. (2012). Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. U.S.A. 109, 19190-19195.
54. Vervoorts, J., Luscher-Firzlaff, J. M., Rottmann, S., Lilischkis, R., Walsemann, G., Dohmann, K., et al. (2003). Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 4, 484-490.
55. Wang, C., Liu, Z., Woo, C. W., Li, Z., Wang, L., Wei, J. S., et al. (2012). EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 72, 315-324.
56. Wood, M. A., McMahon, S. B., and Cole, M. D. (2000). An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. Mol. Cell 5, 321-330.
57. Wu, C. H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., and Felsher, D. W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. U.S.A. 104, 13028-13033.
58. Zaret, K. S., and Carroll, J. S. (2011). Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 25, 2227-2241.
59. Zhang, X. Y., DeSalle, L. M., Patel, J. H., Capobianco, A. J., Yu, D., Thomas-Tikhonenko, A., et al. (2005). Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc. Natl. Acad. Sci. U. S. A. 102, 13968-13973.